Strategic Partnerships TFF has a robust collaboration approach with large pharma and leading medical centers (Emory, Cleveland Clinic, BARDA) and a growing pipeline, presenting multiple co-development and licensing opportunities for inhalable therapies and expanded TFF-enabled products.

Inhalation Focus The patented Thin Film Freezing platform enables a wide range of molecules to be inhaled, suggesting sales opportunities with pharmaceutical partners seeking enhanced pulmonary delivery, improved bioavailability, or novel inhaled formulations for antivirals, antifungals, or immunotherapies.

Lead Programs Lead candidates Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder position TFF in infectious disease and transplant immunosuppression spaces, offering targeted entry points for collaborations or co-development deals to expand into additional indications.

Financial Readiness With significant funding and a recent public offering, plus ongoing collaborations, TFF appears prepared to scale partnerships, fund joint development activities, and potentially license its TFF platform to downstream manufacturers seeking inhalable solutions.

Clinical Momentum Active clinical and preclinical activity, including Phase 2 data presentations and elite academic partnerships, indicates ongoing demand for inhaled therapies and opportunities to position TFF as a preferred platform provider for multicenter trials and translational collaborations.